Welcome to BioSeeker Group!

Current and Future Therapies for Lung Cancer - A Therapeutic and Competitive Insight

Additional Information

Published Date Mar 14, 2006
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 101
PDF Fact Sheet View Fact Sheet for the report Current and Future Therapies for Lung Cancer - A Therapeutic and Competitive Insight in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$1,950.00

Quick Overview

With this report you will be able to track down and foresee activities associated with the development of new treatments for lung cancer.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Current and Future Therapies for Lung Cancer - A Therapeutic and Competitive Insight.

    To find out more about Current and Future Therapies for Lung Cancer - A Therapeutic and Competitive Insight, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Current and Future Therapies for Lung Cancer - A Therapeutic and Competitive Insight is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Introduction

Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer treatment. There are currently two platinum-based compounds that are marketed and clinically used worldwide as treatment for NSCLC: cisplatin and carboplatin. These two drugs are combined with paclitaxel, docetaxel, gemcitabine or vinorelbine to build the first-line treatment options. Several different studies have been comparing or are comparing differ combinations of these drugs. Lately gefitinib, pemetrexed and erlotinib have entered the market and are initially used in second or third-line treatments. The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced NSCLC. However, despite their contributions, science has reached a therapeutic plateau. Both Avastin and Efaproxyn have generated exciting data. In this report we are not only describing the progress of different combinations of approved drugs but as well the progress of 21 late stage drug candidates are described and analysed. Progress profiles and structured information will alow you to pin-point your knowledge-base in a most costeffective way. By gathering information around most drugs under development for lung cancer and specially the late stage pipeline it is has been clear that four major therapeutic strategies generated most interesting data. With this report you will be able to track down and foresee activities associated with the development of new treatments for lung cancer. According to market analytical studies, the NSCLC drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis’ Taxotere (docetaxel), Bristol-Myers Squibb’s Paraplatin (carboplatin) and Eli Lilly’s Gemzar (gemcitabine).

Scope of this report

  • Thorough examination of status and impact of many novel drugs in development
  • Discussion of the challenges in current drug development, including future clinical trials to be made, collaborations and inclusion of novel endpoints.
  • Case studies on major lung cancer drugs on market

Key reasons to read this report

  • Explore the strengths and weaknesses associated with compounds in clinical development.
  • Scientific rationale for novel therapeutics in lung cancer, and the results of clinical trials to date.
  • Gain insight into the current challenges and commercial opportunities associated with lung cancer

Drugs included in this study

Affinitak, Aptosyn, Bevacizumab, Carboxyamidotriazole, Cetuximab, CI-994, Docetaxel, Efaproxyn, Erlotinib, Gefitinib, Gemcitabine, Genasense, Lapatinib IGN-101, Mitumomab, Neovastat, Paclitaxel, Panitumumab, Pemetrexed, Targretin, Telcyta, Tirapazamine, Trastuzumab, Vinflunine, Vinorelbine, Xcytrin, ZD-6474

Companies included in this study

Abgenix, Aphton, AstraZeneca, Bristol-Myers Squibb, Cell Pathways, Eli Lilly, Genentech, Genta, GlaxoSmithKline, ImClone, ISIS Pharmaceuticals, Ligand Pharmaceuticals, OSI Pharmaceuticals, Pfizer, Pharmacyclics, Sanofi-Aventis, Telik

1 Executive Summary

2 Cancer Highlights

3 Methodology

4 4.1 List of boxes
4.2 List of tables
4.3 Appendices

5 Introduction
5.1 Current Treatment Strategies
5.2 Disease Definition
5.3 Etiology & Pathophysiology
5.4 Prognosis
5.5 Epidemiology

6 Progress in current treatment strategies
6.1 Improvements adding microtubule inhibitor
6.2 Improvement of disease related symptoms in elderly patients
6.3 Toxicity profile favored
6.4 A new formula
6.5 Monotherapy?
6.6 Failed to demonstrate a survival advantage
6.7 Reduction in mortality risk

7 Key Drug Strategies in Lung Cancer
7.1 Apoptosis
7.2 Antiangiogenesis and Antivascular Agents
7.2.1 EGFR and VEGFR as target
7.3 Immunotherapy

8 Competitive Landscape in Lung Cancer Drug Development: The Late Stage
Pipeline
8.1 Grade 4 adverse events
8.2 No new remarks
8.3 No significant effect on overall survival
8.4 Bristol Myers Squibb entered into an agreement
8.5 Many uncertainties remain.
8.6 Development terminated
8.7 Continuing Enrollment
8.8 Apoptotic inducer
8.9 Fully-human monoclonal antibody
8.10 Eagerly awaiting data
8.11 Mutations and response
8.12 Statistically and clinically significant survival advantage
8.13 Anti-idiotypic monoclonal antibody
8.14 Shift in the development focus
8.15 Sensitizer
8.16 Treatment in earlier-stage cancer could be more effective
8.17 Discontinued radiosensitizer
8.18 Improvement in chemoradiotherapy
8.19 Progress on HDAC inhibitor
8.20 Progress Analysis Carboxyamidotriazole
8.21 Chemotherapy naïve subjects

9 Disclaimer
9.1 Liability
9.2 Completeness

10 Appendix 1. Treatment Guide Lines*
10.1 References

11 Appendix 2: Selected Company Profiles
11.1 Abgenix
11.2 Aphton
11.3 AstraZeneca
11.4 Bristol-Myers Squibb
11.5 Eli Lilly
11.6 Genentech
11.7 Genta.
11.8 GlaxoSmithKline
11.9 ImClone
11.10 ISIS Pharmaceuticals
11.11 Ligand Pharmaceuticals
11.12 OSI Pharmaceuticals
11.13 Pfizer
11.14 Pharmacyclics
11.15 Sanofi- Aventis
11.16 Telik

12 Appendix 3 Progress profiles on approved drugs
12.1 Docetaxel
12.2 Vinorelbine
12.3 Gemcitabine
12.4 Paclitaxel
12.5 Pemetrexed
12.6 Gefitinib
12.7 Erlotinib

13 Drug Index

14 Company Index

4.1 List of boxes
Box 1: Scientific Data on Docetaxel
Box 2: Quick Facts – Vinorelbine
Box 3: Scientific Data on Vinorelbine
Box 4: Quick Facts – Gemcitabine
Box 5: Scientific Data on gemcitabine
Box 6: Scientific Data on Pemetrexed
Box 7: Quick Facts – pemetrexed
Box 8: Quick Facts – Gefitinib
Box 9: Scientific Data on Gefitinib
Box 10: Quick Facts – Erlotinib

4.2 List of tables
Table 1: Chemotherapeutic drugs for treatment of NSCLC
Table 2. Near Term Approved Drugs for the Treatment of NSCLC
Table 3: Chemotherapy Drugs off Patent
Table 4 Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways.
Table 5 VTA agents under development
Table 6 EGFR or VEGFR inhibitors
Table 7: FMS-like tyrosine kinases and their Synonyms
Table 8: Fms-related Tyrosine Kinase Targets in Development
Table 9: Protein Kinase Targets in Clinical Trials for Lung Cancer
Table 10 Cancer immunotherapy strategies
Table 11 Recently presented studies Lapatinib
Table 12 Recently presented studies ZD-6474
Table 13 Recently presented studies vinflunine
Table 14 Recently presented studies Panitumumab
Table 15 Recently presented studies Genasense
Table 16 Recently presented studies cetuximab
Table 17 Recently presented studies bevacizumab
Table 18 Recently presented studies bexarotene1
Table 19 Recently presented studies Xcytrin

4.3 Appendices
10 Appendix 1. Treatment Guide Lines*
11 Appendix 2: Selected Company Profiles
12 Appendix 3 Progress profiles on approved drugs

- Abgenix
- Aphton
- AstraZeneca
- Bristol-Myers Squibb
- Cell Pathways
- Eli Lilly
- Genentech
- Genta
- GlaxoSmithKline
- ImClone
- ISIS Pharmaceuticals
- Ligand Pharmaceuticals
- OSI Pharmaceuticals
- Pfizer
- Pharmacyclics
- Sanofi-Aventis
- Telik
Drugs included in this study:
Affinitak
Aptosyn
Bevacizumab
Carboxyamidotriazole
Cetuximab
CI-994
Docetaxel
Efaproxyn
Erlotinib
Gefitinib
Gemcitabine
Genasense
Lapatinib IGN-101
Mitumomab
Neovastat
Paclitaxel
Panitumumab
Pemetrexed
Targretin
Telcyta
Tirapazamine
Trastuzumab
Vinflunine
Vinorelbine
Xcytrin
ZD-6474

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Current and Future Therapies for Lung Cancer - A Therapeutic and Competitive Insight.
    To find out more about Current and Future Therapies for Lung Cancer - A Therapeutic and Competitive Insight, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Current and Future Therapies for Lung Cancer - A Therapeutic and Competitive Insight is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Melanoma - Targeted Therapeutics
This in-depth analysis of the progress of melanoma R&D and current treatment strategies is one of the most extensive reports available in this field. Learn More


The Drug Target Atlas of Protein Kinase Inhibitors in Oncology
This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of new protein kinase inhibitor drugs in oncology. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Colorectal Cancer, Pancreatic Cancer and Apoptosis
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Pancreatic Cancer and by the mechanism/target/effect of Apoptosis. Learn More


Notch Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 335 companies plus partners who are today developing 416 Notch pathway targeting drugs in 1497 developmental projects in cancer across 232 different targets. In addition, there are 4 suspended drugs and another 236 drugs where development has been ceased. Learn More